Showing results (121-130 of 184) with videos related to

Sort By:
Pageof 19
Rheumatology (Oxford, England)|August 24, 2011
Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factorsSarah L Mackie, Bhaskar Dasgupta, Lesley Hordon, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb studyMark C Genovese, Roy Fleischmann, Daniel Furst, et al.
Rheumatology (Oxford, England)|December 23, 2020
Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight lossKornelis S M van der Geest, Konrad Wolfe, Frances Borg, et al.
Frontiers in Medicine|February 12, 2024
Diagnostic accuracy of OGUS, Southend halo score and halo count in giant cell arteritisEdoardo Conticini, Paolo Falsetti, Suhel Gabriele Al Khayyat, et al.
RMD Open|November 2, 2019
Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitisAna F Águeda, Sara Monti, Raashid Ahmed Luqmani, et al.
Arthritis and Rheumatism|April 3, 2008
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging studyJonathan Kay, Eric L Matteson, Bhaskar Dasgupta, et al.
Rheumatology (Oxford, England)|October 31, 2021
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extensionJohn H Stone, Helen Spotswood, Sebastian H Unizony, et al.
Rheumatology (Oxford, England)|December 19, 2019
The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritisSara Monti, Cristina Ponte, Claudio Pereira, et al.
The Lancet. Rheumatology|January 27, 2024
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trialJohn H Stone, Jian Han, Martin Aringer, et al.
Seminars in Arthritis and Rheumatism|December 22, 2016
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trialKatie Tuckwell, Neil Collinson, Sophie Dimonaco, et al.
Pageof 19